Trial Profile
Phase 1B Open-Label, Dose-Escalation and Dose-Expansion Study of APVO436 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndrome (MDS)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs APVO-436 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Aptevo Therapeutics
- 13 Dec 2022 Interim Results (n=30, from the dose-expansion phase) assessing safety and tolerability of APVO436 in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 09 Jun 2022 Results presented in an Aptevo Therapeutics Media Release.
- 29 Mar 2022 Results presented in an Aptevo Therapeutics media release.